Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer. Following a period of restricted access, the once-a-day capsule will ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

The post hailed “promising results” from a trial of GSK’s PARP inhibitor niraparib in brain cancer patients; the drug, sold as Zejula, is currently approved as a maintenance treatment for ...

GlaxoSmithKline said it will raise prices ... its recently acquired cancer drug Zejula and on several products in its HIV-focused ViiV joint venture, according to 3 Axis Advisors.

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

GSK plc GSK reported fourth-quarter 2024 core ... it received approval in the EU in January 2024. Zejula sales fell 3% in the quarter. Though the drug’s U.S. sales were adversely impacted ...

The vaccines business – where GSK is among the global leaders – did ... thanks to a surge in the sale of cancer drugs Jemperli and Zejula. To offer further encouragement, Dame Emma Walmsley, ...

In December 2024, GSK reported that the Phase III FIRST-ENGOT-OV44 trial of Zejula and Jemperli met its primary endpoint of progression-free survival in treating first-line advanced ovarian cancer.